KR20150018789A - 암의 치료를 위한 피리미딘 화합물 - Google Patents
암의 치료를 위한 피리미딘 화합물 Download PDFInfo
- Publication number
- KR20150018789A KR20150018789A KR1020147032028A KR20147032028A KR20150018789A KR 20150018789 A KR20150018789 A KR 20150018789A KR 1020147032028 A KR1020147032028 A KR 1020147032028A KR 20147032028 A KR20147032028 A KR 20147032028A KR 20150018789 A KR20150018789 A KR 20150018789A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- alkyl
- group
- cycloalkyl
- compound according
- Prior art date
Links
- 0 C*(C)c1ccc(C=O)[o]1 Chemical compound C*(C)c1ccc(C=O)[o]1 0.000 description 5
- PCEQSNRCUACAIR-CPISYKEBSA-N CCCCNc(nc1)nc(/N=C(\CC2)/CC[C@H]2O)c1-c(cc1)ncc1F Chemical compound CCCCNc(nc1)nc(/N=C(\CC2)/CC[C@H]2O)c1-c(cc1)ncc1F PCEQSNRCUACAIR-CPISYKEBSA-N 0.000 description 1
- GRBOOQSMKBGRQB-ZQHRETPFSA-N CCCCNc(nc1)nc(/N=C(\CC2)/CC[C@H]2O)c1-c1ccc(CN2CCN(C)CC2)[o]1 Chemical compound CCCCNc(nc1)nc(/N=C(\CC2)/CC[C@H]2O)c1-c1ccc(CN2CCN(C)CC2)[o]1 GRBOOQSMKBGRQB-ZQHRETPFSA-N 0.000 description 1
- XDOAHMKLQCBJAR-IPHDDYSGSA-N CCCCNc(nc1)nc(/N=C(\CC2)/CC[C@H]2O)c1Br Chemical compound CCCCNc(nc1)nc(/N=C(\CC2)/CC[C@H]2O)c1Br XDOAHMKLQCBJAR-IPHDDYSGSA-N 0.000 description 1
- YOWVMBDVLNKABE-UHFFFAOYSA-N CCCCNc(nc1)nc(N)c1-c1ccc(C=O)[o]1 Chemical compound CCCCNc(nc1)nc(N)c1-c1ccc(C=O)[o]1 YOWVMBDVLNKABE-UHFFFAOYSA-N 0.000 description 1
- DQXNTSXKIUZJJS-UHFFFAOYSA-N Cc(cnc(Cl)n1)c1Cl Chemical compound Cc(cnc(Cl)n1)c1Cl DQXNTSXKIUZJJS-UHFFFAOYSA-N 0.000 description 1
- OTCYOBLTAQTFPW-UHFFFAOYSA-N NC(CC1)CCC1=O Chemical compound NC(CC1)CCC1=O OTCYOBLTAQTFPW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261650000P | 2012-05-22 | 2012-05-22 | |
US61/650,000 | 2012-05-22 | ||
PCT/US2013/042033 WO2013177168A1 (en) | 2012-05-22 | 2013-05-21 | Pyrimidine compounds for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20150018789A true KR20150018789A (ko) | 2015-02-24 |
Family
ID=49624289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020147032028A KR20150018789A (ko) | 2012-05-22 | 2013-05-21 | 암의 치료를 위한 피리미딘 화합물 |
Country Status (14)
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
CA2850617A1 (en) | 2011-10-03 | 2013-04-11 | The University Of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
WO2013177168A1 (en) | 2012-05-22 | 2013-11-28 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
WO2014058685A1 (en) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
CN104926801B (zh) * | 2014-03-22 | 2019-06-04 | 浙江大学 | 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用 |
WO2015157125A1 (en) * | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Therapuetic uses of selected pyrazolopyrimidine compounds with anti-mer tyrosine kinase activity |
WO2017059280A1 (en) * | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
US10710983B2 (en) * | 2016-06-27 | 2020-07-14 | Rigel Pharmaceuticals, Inc. | 2,4-diamino-pyrimidine compounds and method for making and using the compounds |
CN106749173A (zh) * | 2016-11-25 | 2017-05-31 | 吉林化工学院 | 一种嘧啶联吡啶类化合物的制备方法 |
CN110831937A (zh) * | 2017-05-02 | 2020-02-21 | 韩国化学研究院 | 嘧啶衍生物化合物、其光学异构体或其药学上可接受的盐及包含其为有效成分的Tyro3相关疾病的预防或治疗用组合物 |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
WO2022059996A1 (ko) * | 2020-09-15 | 2022-03-24 | 서울대학교 기술지주 주식회사 | 혈액 순환 미세체외소체 매개 암 치료용 조성물 |
KR102616469B1 (ko) * | 2020-09-15 | 2023-12-28 | 주식회사 유엔에스바이오 | 혈액 순환 미세체외소체 매개 암 치료용 조성물 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH549339A (de) * | 1971-05-12 | 1974-05-31 | Ciba Geigy Ag | Herbizides mittel. |
US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
US20080248046A1 (en) | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
MXPA02010693A (es) * | 2000-04-28 | 2003-03-10 | Tanabe Seiyaku Co | Compuestos ciclicos. |
GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
ES2309206T3 (es) | 2001-10-02 | 2008-12-16 | Smithkline Beecham Corporation | Compuestos quimicos. |
MXPA04012855A (es) * | 2002-06-28 | 2005-04-19 | Yamanouchi Pharma Co Ltd | Derivado de diaminopirimidincarboxiamida. |
DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
WO2004106340A2 (en) | 2003-05-28 | 2004-12-09 | Università Degli Studi Di Siena | 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF |
US7504396B2 (en) * | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
KR20060070572A (ko) | 2003-09-18 | 2006-06-23 | 콘포마 세러퓨틱스 코포레이션 | Hsp90-저해제로서의 신규 헤테로시클릭 화합물 |
EP2260849A1 (en) | 2004-01-21 | 2010-12-15 | Emory University | Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection |
JP2007520559A (ja) | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
JP4989233B2 (ja) | 2004-02-14 | 2012-08-01 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
WO2005095382A1 (ja) | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | 抗腫瘍剤 |
EP1732541A4 (en) | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
AU2005288864B2 (en) * | 2004-09-30 | 2012-08-23 | Janssen Sciences Ireland Uc | HIV inhibiting 5-heterocyclyl pyrimidines |
US7906528B2 (en) | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
WO2007032445A1 (ja) | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
US20070105874A1 (en) | 2005-09-23 | 2007-05-10 | Conforma Therapeutics Corporation | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
CN101321751A (zh) * | 2005-09-30 | 2008-12-10 | 布里斯托尔-迈尔斯·斯奎布公司 | Met激酶抑制剂 |
US7547782B2 (en) * | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
AR055206A1 (es) | 2005-10-06 | 2007-08-08 | Schering Corp | Pirazolo[1, 5 - a]pirimidinas como inhibidoras de proteina quinasa, composiciones farmaceuticas y combinaciones con agentes citostaticos que las comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer. |
SI1957539T1 (sl) | 2005-12-08 | 2013-05-31 | Medarex, Inc. | Humana monoklonska protitelesa proti protein tirozin kinazi 7 (PTK7) in njihova uporaba |
JP2009520028A (ja) | 2005-12-19 | 2009-05-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Igfr抑制剤および抗癌剤の併用 |
EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
EP2004632B1 (en) * | 2006-03-30 | 2014-03-12 | Janssen R&D Ireland | Hiv inhibiting 5-amido substituted pyrimidines |
JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換2−アミノ縮合複素環式化合物 |
GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
TW200901975A (en) | 2007-03-05 | 2009-01-16 | Kyowa Hakko Kogyo Kk | Pharmaceutical composition |
AU2008296479A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
EP2212297B1 (en) | 2007-10-12 | 2011-05-25 | Ingenium Pharmaceuticals GmbH | Inhibitors of protein kinases |
WO2009062112A2 (en) | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as antimicrobials |
US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
ES2711249T3 (es) * | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
US8399206B2 (en) | 2008-07-10 | 2013-03-19 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
WO2010014755A1 (en) | 2008-07-29 | 2010-02-04 | The Regents Of The University Of Colorado | Methods and compounds for enhancing anti-cancer therapy |
WO2010030781A2 (en) | 2008-09-10 | 2010-03-18 | Numed International, Inc. | Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer |
WO2010038081A2 (en) * | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
GB0819105D0 (en) | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
US8765727B2 (en) | 2009-01-23 | 2014-07-01 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
WO2010117425A1 (en) | 2009-03-31 | 2010-10-14 | Biogen Idec Ma Inc. | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
WO2011020024A2 (en) | 2009-08-13 | 2011-02-17 | The Johns Hopkins University | Methods of modulating immune function |
BR112012005400A2 (pt) | 2009-09-10 | 2016-04-05 | Irm Llc | derivados do tipo éter de heteroarilas bicíclicas |
WO2011065800A2 (ko) * | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
EP2536410B1 (en) | 2010-02-18 | 2015-09-23 | Merck Sharp & Dohme Corp. | Substituted pyrimidine derivatives and their use in treating viral infections |
GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
CN103221048A (zh) | 2010-11-18 | 2013-07-24 | 卡斯纳莱拉创新药物私人有限公司 | 取代的4-(硒吩-2(或3)-基氨基)嘧啶化合物及其使用方法 |
US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
WO2013032591A1 (en) * | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
JP5914667B2 (ja) | 2011-09-22 | 2016-05-11 | ファイザー・インク | ピロロピリミジンおよびプリン誘導体 |
CA2850617A1 (en) | 2011-10-03 | 2013-04-11 | The University Of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
IN2014DN07022A (US07138402-20061121-C00069.png) | 2012-02-21 | 2015-04-10 | Inst Nat Sante Rech Med | |
EP2840080B1 (en) * | 2012-04-17 | 2017-12-06 | FUJIFILM Corporation | Nitrogen-containing heterocyclic compound or salt thereof |
CN104662018B (zh) | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
WO2013177168A1 (en) | 2012-05-22 | 2013-11-28 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
WO2015153978A1 (en) | 2014-04-04 | 2015-10-08 | The University Of North Carolina At Chapel Hill | Methods for the treatment of tumors |
WO2015157125A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Therapuetic uses of selected pyrazolopyrimidine compounds with anti-mer tyrosine kinase activity |
-
2013
- 2013-05-21 WO PCT/US2013/042033 patent/WO2013177168A1/en active Application Filing
- 2013-05-21 CN CN201380025291.3A patent/CN104302627A/zh active Pending
- 2013-05-21 RU RU2014145121A patent/RU2014145121A/ru not_active Application Discontinuation
- 2013-05-21 EP EP13793925.2A patent/EP2852579A4/en not_active Withdrawn
- 2013-05-21 BR BR112014028424A patent/BR112014028424A2/pt not_active Application Discontinuation
- 2013-05-21 KR KR1020147032028A patent/KR20150018789A/ko not_active Application Discontinuation
- 2013-05-21 JP JP2015514115A patent/JP2015517574A/ja active Pending
- 2013-05-21 AU AU2013266438A patent/AU2013266438B2/en not_active Expired - Fee Related
- 2013-05-21 MX MX2014013632A patent/MX2014013632A/es unknown
- 2013-05-21 CA CA2873878A patent/CA2873878A1/en not_active Abandoned
- 2013-05-21 IN IN9610DEN2014 patent/IN2014DN09610A/en unknown
- 2013-05-21 US US14/384,789 patent/US9567326B2/en active Active
-
2014
- 2014-11-16 IL IL235726A patent/IL235726A0/en unknown
-
2015
- 2015-07-20 HK HK15106878.7A patent/HK1206338A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
MX2014013632A (es) | 2015-02-05 |
BR112014028424A2 (pt) | 2018-04-24 |
AU2013266438A1 (en) | 2014-12-04 |
JP2015517574A (ja) | 2015-06-22 |
IN2014DN09610A (US07138402-20061121-C00069.png) | 2015-07-31 |
US20150038481A1 (en) | 2015-02-05 |
CN104302627A (zh) | 2015-01-21 |
AU2013266438B2 (en) | 2017-09-07 |
HK1206338A1 (en) | 2016-01-08 |
WO2013177168A1 (en) | 2013-11-28 |
EP2852579A1 (en) | 2015-04-01 |
EP2852579A4 (en) | 2015-12-30 |
CA2873878A1 (en) | 2013-11-28 |
US9567326B2 (en) | 2017-02-14 |
IL235726A0 (en) | 2015-02-01 |
RU2014145121A (ru) | 2016-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20150018789A (ko) | 암의 치료를 위한 피리미딘 화합물 | |
JP6316925B2 (ja) | 癌を治療するためのピロロピリミジン化合物 | |
US9771330B2 (en) | Pyrimidine compounds for the treatment of cancer | |
US9744172B2 (en) | Pyrazolopyrimidine compounds for the treatment of cancer | |
US9562047B2 (en) | Pyrazolopyrimidine compounds for the treatment of cancer | |
US20080319044A1 (en) | Compounds and Methods of Use Thereof | |
WO2020156479A1 (zh) | 环丙烯并苯并呋喃取代的氮杂芳基化合物、其中间体、制备方法及应用 | |
EP4274559A1 (en) | Modulators of programmed death-ligand-1 | |
ES2253380T3 (es) | Bis-(n,n'-bis-(2-haloetil)amino)fosforamidatos como agentes antitumorales. | |
TW202327601A (zh) | 芳胺類衍生物及其製備方法和醫藥用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |